Age (y/o) |
52.3 ± 13.5 |
55.3 ± 15.0 |
0.254 |
Male (n, %) |
58 (58.6%) |
32 (80.0%) |
0.019 |
Hypertension (n, %) |
17 (17.2%) |
6 (15.0%) |
1.000 |
Diabetes (n, %) |
8 (8.1%) |
3 (7.5%) |
1.000 |
Symptom of Palpitation (n, %) |
97 (98.0%) |
40 (100.0%) |
1.000 |
Symptom of Syncope (n, %) |
10 (10.1%) |
7 (17.5%) |
0.257 |
Medication before ablation |
|
|
|
Beta blocker or CCB only (n, %) |
39 (39.4%) |
15 (37.5%) |
1.000 |
Class I AAD (n, %) |
36 (36.4%) |
13 (32.5%) |
0.700 |
Amiodarone (n, %) |
19 (19.2%) |
12 (30.0%) |
0.182 |
Clinical VA pattern |
|
|
|
Presence of Sustained VT (n, %) |
13 (13.1%) |
12 (30.0%) |
0.027 |
Presence of Non-Sustained VT (n, %) |
33 (33.3%) |
9 (22.5%) |
0.228 |
PVC burden (pre-ablation) (beats/day) |
22467 ± 12419 |
20597 ± 12307 |
0.510 |
PVC burden (pre-ablation) (%)* |
20.9 ± 11.6 |
20.0 ± 11.6 |
0.631 |
Ejection fraction (pre-ablation) (%)* |
58.4 ± 4.1 |
37.5 ± 9.3 |
<0.001 |
VA morphology |
|
|
|
RBBB morphology (n,%) |
27 (27.3%) |
19 (47.5%) |
0.029 |
Coupling interval |
483.7 ± 58.8 |
510.5 ± 66.4 |
0.021 |
QRSd, ms |
147.2 ± 20.4 |
163.7 ± 28.0 |
0.001 |
IDT, ms |
58.2 ± 20.8 |
63.8 ± 21.9 |
0.155 |
PdW, ms |
56.9 ± 20.7 |
59.9 ± 20.4 |
0.438 |
Q-wave aVL/aVR ratio |
1.36 ± 0.48 |
1.49 ± 0.39 |
0.130 |
MDI |
0.47 ± 0.13 |
0.46 ± 0.13 |
0.617 |
Successful ablation site (n, %) |
|
|
|
ASV |
38 (38.4%) |
11 (27.5%) |
0.246 |
Subvalvular |
21 (21.2%) |
8 (20.0%) |
1.000 |
GCV/AIV |
28 (28.3%) |
15 (37.5%) |
0.315 |
Epicardium |
12 (12.1%) |
6 (15.0%) |
0.781 |
AEAD |
12.0 ± 9.1 |
16.3 ± 8.2 |
0.012 |
Multiple site ablation requirement (n, %) |
56 (56.6%) |
22 (55.0%) |
1.000 |